The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Pittsburgh

The Children's Hospital of Philadelphia

Dontcho V Jelev

Dimiter Stanchev Dimitrov

Zhongyu Zhu

Wei Li

John W Mellors

John M Maris

Kristopher R Bosse

Chuan Chen

Zehua Sun

The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen.

Glypican 2 as a cancer marker and therapeutic target

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) to a SARS-CoV-2 antigen. For example, binders (e.g., antibodies, antigen binding fragments, and antibody domains) that bind to a SARS-CoV-2 polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having COVID-19 (or a viral infection caused by SARS-CoV-2) are provided.

Molecules that bind to SARS-CoV-2

Growing community of inventors

Rockville, MD, United States of America

Dontcho V Jelev